新加坡癌症早筛龙头企业Mirxes Holding Limited（股票代号：02629.HK，下称"Mirxes觅瑞"），自2025 年5月23日在港交所主板上市后，仅用不足四个月便先后纳入恒生综合指数与港股通标的，其价值获国 际市场高度认可，也为内地投资者开辟了参与生物科技独角兽成长的新路径。 "公司上市不足四个月便纳入恒生综合指数，我们深感荣幸。"Mirxes觅瑞联合创始人兼首席执行官周砺 寒博士表示，"这印证了我们选择在港交所上市的战略正确性，也进一步彰显了公司扩大全球投资者范 围的坚定承诺。" 【关于Mirxes觅瑞】 2025年9月5日香港交易所收市后，恒生指数公司季度检讨结果正式生效，Mirxes觅瑞成功跻身沪港通下 港股通标的名单。自9月8日（星期一）起，这家新加坡生物科技企业正式向内地投资者开放，标志着其 投资者群体将进一步扩容。作为连接内地与香港股市的核心机制，港股通的纳入门槛围绕市值、流动 性、上市表现等关键指标展开，而恒生指数公司每半年一次的系统性指数检讨，正是为了确保标的组合 的代表性与平衡性。Mirxes觅瑞此次"双纳入"，本质是市场对其综合实力的深度肯定。 Mirxes觅瑞（股票 ...

Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, reaching a new high of 40.66 HKD, which is over 70% higher than its IPO price of 23.3 HKD [1] Company Overview - Mirxes is a Singapore-based RNA biotechnology company focused on developing and commercializing precise, non-invasive, and affordable blood miRNA tests for early cancer and disease screening [1] - The flagship product, GASTROClear™/觅小卫™, is a blood miRNA-based molecular diagnostic kit for gastric cancer screening, approved in multiple countries including Singapore and the EU, and has received breakthrough medical device certification from the US FDA [1] - GASTROClear™ has completed a prospective clinical trial with a sample size of 9,472 in China and is currently in the registration application process [1] Market Position - The company is recognized as a global leader in the field of early cancer detection based on miRNA, possessing significant technological, product, and market advantages [1] - The global cancer screening market is noted to have vast potential with high entry barriers [1] - GASTROClear™ is the only approved molecular diagnostic IVD product for gastric cancer screening in the global market, holding the largest market share of 66.3% in the Southeast Asian miRNA-based liquid biopsy gastric cancer screening market as of 2023 [1]

Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, reaching a new high of 40.66 HKD, which is over 70% higher than its IPO price of 23.3 HKD [1] Company Overview - Mirxes is a Singapore-based RNA biotechnology company focused on developing and commercializing precise, non-invasive, and affordable blood miRNA tests for early cancer and other disease screening [1] - The flagship product, GASTROClear™/觅小卫™, is a blood miRNA-based molecular diagnostic kit for gastric cancer screening, approved in multiple countries including Singapore and the EU, and has received breakthrough medical device certification from the US FDA [1] - GASTROClear™ has completed a prospective clinical trial with a sample size of 9,472 in China and is currently in the registration application process [1] Market Position - According to Guoyuan International, the company holds significant technological, product, and market advantages in the field of miRNA-based early cancer detection, positioning it as a global leader [1] - Everbright Securities International noted the vast market potential for global cancer screening, highlighting high industry entry barriers [1] - GASTROClear™ is the only approved molecular diagnostic IVD product for gastric cancer screening globally, holding the largest market share of 66.3% in the Southeast Asian miRNA liquid biopsy gastric cancer screening market as of 2023 [1]